Investigation of the Biochemical Changes of Sialidosis Disease and Its Relationship with NEU1 Gene in Two Khuzestanian Families by WES Method

How to Cite:Jalali N A, Moradzadegan A, Investigation of the Biochemical Changes of Sialidosis Disease and Its Relationship with NEU1 Gene in Two Khuzestanian Families by WES Method.koomesh.2024;26(5):e155641.https://doi.org/10.69107/koomesh-155641.

Abstract

Background and Objectives: Sialidosis (MIM 256550) is a rare, autosomal recessive inherited disorder caused by α-N-acetyl neuraminidase deficiency due to a mutation in the neuraminidase gene (NEU1) located at chromosomal locus 6p21.33. This genetic change leads to abnormal intracellular accumulation and urinary excretion of sialyloligosaccharides. The diagnostic method based on WES (Whole-Exome Sequencing) technology saves time and cost and provides the basis for more appropriate genetic counseling.

Methods: In this case-descriptive study, after taking samples from patients and their parents in a tube containing EDTA anticoagulant, DNA extraction was performed using the saturated salt method, and the genomes of the patients were analyzed using the whole genome sequencing technique. The found variant was checked for confirmation by the parents using the standard Sanger sequencing technique. For this purpose, the PCR (polymerase chain reaction) method was used to amplify the target fragment, and the Chromas program was used to read the data.

Results: The NM_00043: exon3: c. G451A: p.V1511I variant was identified as homozygous in the patient of the first family. This variant was confirmed in the patient's parents.

Conclusion: The results of this study showed that the identification of new harmful variants in this gene can help to complete the relevant genetic panel and accelerate the identification of patients with sialidosis phenotype.

Keywords

Exome Sequencing

References

1.
Khan A, Sergi C. Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder. Diagnostics (Basel). 2018;8(2). [PubMed ID:29693572]. [PubMed Central ID:PMC6023449]. https://doi.org/10.3390/diagnostics8020029.
2.
Seyrantepe V, Poupetova H, Froissart R, Zabot MT, Maire I, Pshezhetsky AV. Molecular pathology of NEU1 gene in sialidosis. Hum Mutat. 2003;22(5):343-52. [PubMed ID:14517945]. https://doi.org/10.1002/humu.10268.
3.
Hunter CD, Porter EM, Cairo CW. Human neuraminidases have reduced activity towards modified sialic acids on glycoproteins. Carbohydr Res. 2020;497:108139. [PubMed ID:32911203]. https://doi.org/10.1016/j.carres.2020.108139.
4.
Bonten E, van der Spoel A, Fornerod M, Grosveld G, d'Azzo A. Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes Dev. 1996;10(24):3156-69. [PubMed ID:8985184]. https://doi.org/10.1101/gad.10.24.3156.
5.
Khan SA, Tomatsu SC. Mucolipidoses Overview: Past, Present, and Future. Int J Mol Sci. 2020;21(18). [PubMed ID:32957425]. [PubMed Central ID:PMC7555117]. https://doi.org/10.3390/ijms21186812.
6.
Coppola A, Ianniciello M, Vanli-Yavuz EN, Rossi S, Simonelli F, Castellotti B, et al. Diagnosis and Management of Type 1 Sialidosis: Clinical Insights from Long-Term Care of Four Unrelated Patients. Brain Sci. 2020;10(8). [PubMed ID:32752208]. [PubMed Central ID:PMC7465165]. https://doi.org/10.3390/brainsci10080506.
7.
Lukong KE, Elsliger MA, Chang Y, Richard C, Thomas G, Carey W, et al. Characterization of the sialidase molecular defects in sialidosis patients suggests the structural organization of the lysosomal multienzyme complex. Hum Mol Genet. 2000;9(7):1075-85. [PubMed ID:10767332]. https://doi.org/10.1093/hmg/9.7.1075.
8.
Lee W, Lee SYL. Diagnostic challenges in distinguishing autism spectrum disorder from psychosis: A case report. European Psychiatry. 2023;66(S1):S1092-S3.
9.
Ortiz-Martinez M, Flores-DelaToba R, Gonzalez-Gonzalez M, Rito-Palomares M. Current Challenges and Future Trends of Enzymatic Paper-Based Point-of-Care Testing for Diabetes Mellitus Type 2. Biosensors (Basel). 2021;11(12). [PubMed ID:34940239]. [PubMed Central ID:PMC8699572]. https://doi.org/10.3390/bios11120482.
10.
Abtahi H, Salmanian AH. [Antigenicity of recombinant L7/L12 in patients with brucellosis]. Koomesh. 2012;13(2):e152504. Persian.
11.
Goh G, Choi M. Application of whole exome sequencing to identify disease-causing variants in inherited human diseases. Genomics Inform. 2012;10(4):214-9. [PubMed ID:23346032]. [PubMed Central ID:PMC3543920]. https://doi.org/10.5808/GI.2012.10.4.214.
12.
Vilarinho S, Mistry PK. Exome Sequencing in Clinical Hepatology. Hepatol. 2019;70(6):2185-92. [PubMed ID:31222768]. [PubMed Central ID:PMC6885087]. https://doi.org/10.1002/hep.30826.
13.
Jakubek YA, Cutler DJ. A model of binding on DNA microarrays: understanding the combined effect of probe synthesis failure, cross-hybridization, DNA fragmentation and other experimental details of affymetrix arrays. BMC Genomics. 2012;13:737. [PubMed ID:23270536]. [PubMed Central ID:PMC3548757]. https://doi.org/10.1186/1471-2164-13-737.
14.
Bumgarner R. Overview of DNA microarrays: types, applications, and their future. Curr Protoc Mol Biol. 2013;Chapter 22:Unit 22 1. [PubMed ID:23288464]. [PubMed Central ID:PMC4011503]. https://doi.org/10.1002/0471142727.mb2201s101.
15.
Esplin ED, Oei L, Snyder MP. Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. Pharmacogenomics. 2014;15(14):1771-90. [PubMed ID:25493570]. [PubMed Central ID:PMC4336568]. https://doi.org/10.2217/pgs.14.117.
16.
d'Azzo A, Machado E, Annunziata I. Pathogenesis, Emerging therapeutic targets and Treatment in Sialidosis. Expert Opin Orphan Drugs. 2015;3(5):491-504. [PubMed ID:26949572]. [PubMed Central ID:PMC4777310]. https://doi.org/10.1517/21678707.2015.1025746.
17.
Flores-Contreras EA, Garcia-Ortiz JE, Robles-Espinoza CD, Zomosa-Signoret V, Becerra-Solano LE, Vidaltamayo R, et al. Clinical Exome Sequencing Enables Congenital Sialidosis Type II Diagnosis in Two Siblings Presenting with Unreported Clinical Features from a Rare Homozygous Sequence Variant p.(Tyr370Cys) in NEU1. Mol Syndromol. 2021;12(4):250-7. [PubMed ID:34421504]. [PubMed Central ID:PMC8339489]. https://doi.org/10.1159/000515081.
18.
Rodriguez Criado G, Pshezhetsky AV, Rodriguez Becerra A, Gomez de Terreros I. Clinical variability of type II sialidosis by C808T mutation. Am J Med Genet A. 2003;116A(4):368-71. [PubMed ID:12522793]. https://doi.org/10.1002/ajmg.a.10710.
19.
Mosca R, van de Vlekkert D, Campos Y, Fremuth LE, Cadaoas J, Koppaka V, et al. Conventional and Unconventional Therapeutic Strategies for Sialidosis Type I. J Clin Med. 2020;9(3). [PubMed ID:32143456]. [PubMed Central ID:PMC7141319]. https://doi.org/10.3390/jcm9030695.
20.
Caciotti A, Melani F, Tonin R, Cellai L, Catarzi S, Procopio E, et al. Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: An overview. Mol Genet Metab. 2020;129(2):47-58. [PubMed ID:31711734]. https://doi.org/10.1016/j.ymgme.2019.09.005.
21.
Maroofian R, Schuele I, Najafi M, Bakey Z, Rad A, Antony D, et al. Parental Whole-Exome Sequencing Enables Sialidosis Type II Diagnosis due to an NEU1 Missense Mutation as an Underlying Cause of Nephrotic Syndrome in the Child. Kidney Int Rep. 2018;3(6):1454-63. [PubMed ID:30450471]. [PubMed Central ID:PMC6224678]. https://doi.org/10.1016/j.ekir.2018.07.015.

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

CrossRef 0

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Nikoo Alsadat Jalali:[PubMed][Scholar]
Atousa Moradzadegan:[PubMed][Scholar]